NDANASALSPRAY, METERED
Approved
Mar 2017
Lifecycle
Peak
Competitive Pressure
8/100
Clinical Trials
1
Data completeness
5/8 — Partial
NOCTIVA (desmopressin acetate) by Ferring Pharmaceuticals is acetate's primary pharmacodynamic action involves its binding to vasopressin 2 (v2) receptors. Approved for nocturia. First approved in 2017.
Drug data last refreshed 20h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NOCTIVA (desmopressin acetate) is a nasal spray small molecule that treats nocturia by binding to V2 receptors in the kidney to increase water reabsorption and reduce nighttime urination. It is a synthetic analog of vasopressin designed to selectively enhance antidiuretic activity while minimizing vasopressor effects. The drug addresses a common quality-of-life condition affecting millions of patients with frequent nighttime urination.
Peak4.1 years to LOE
Product is at peak revenue stage within a moderately competitive market (competitive pressure 8/10), suggesting stable commercial teams and ongoing optimization initiatives rather than rapid expansion.
Mechanism of Action
acetate's primary pharmacodynamic action involves its binding to vasopressin 2 (V2) receptors. V2 receptors are primarily located in the distal convoluted tubule and collecting ducts of the nephron in the kidneys. These receptors play a crucial role in regulating water reabsorption and urine…
Indications (1)
Clinical Trials (1)
Desmopressin Acetate 0.2 mg Tablets, Fasting
Started Jul 2003
48 enrolled
Healthy
Why This Matters for Your Career
Worked on NOCTIVA at Ferring Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.